KR20220034857A - 알츠하이머병의 치료를 위한 중화 항-아밀로이드 베타 항체 - Google Patents

알츠하이머병의 치료를 위한 중화 항-아밀로이드 베타 항체 Download PDF

Info

Publication number
KR20220034857A
KR20220034857A KR1020227004730A KR20227004730A KR20220034857A KR 20220034857 A KR20220034857 A KR 20220034857A KR 1020227004730 A KR1020227004730 A KR 1020227004730A KR 20227004730 A KR20227004730 A KR 20227004730A KR 20220034857 A KR20220034857 A KR 20220034857A
Authority
KR
South Korea
Prior art keywords
ser
val
gly
thr
leu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020227004730A
Other languages
English (en)
Korean (ko)
Inventor
밍 진
로랑 프라디에
데이비드 레젝
데니스 셀코에
타라 트라발린
도미닉 왈쉬
Original Assignee
사노피
더 브리검 앤드 우먼즈 하스피털, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 사노피, 더 브리검 앤드 우먼즈 하스피털, 인크. filed Critical 사노피
Publication of KR20220034857A publication Critical patent/KR20220034857A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
KR1020227004730A 2019-07-16 2020-07-15 알츠하이머병의 치료를 위한 중화 항-아밀로이드 베타 항체 Pending KR20220034857A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962874724P 2019-07-16 2019-07-16
US62/874,724 2019-07-16
PCT/US2020/042161 WO2021011673A2 (en) 2019-07-16 2020-07-15 Neutralizing anti-amyloid beta antibodies for the treatment of alzheimer's disease

Publications (1)

Publication Number Publication Date
KR20220034857A true KR20220034857A (ko) 2022-03-18

Family

ID=71895293

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227004730A Pending KR20220034857A (ko) 2019-07-16 2020-07-15 알츠하이머병의 치료를 위한 중화 항-아밀로이드 베타 항체

Country Status (6)

Country Link
EP (1) EP3999532A2 (enExample)
JP (1) JP7685985B2 (enExample)
KR (1) KR20220034857A (enExample)
CN (3) CN121800915A (enExample)
CA (1) CA3147239A1 (enExample)
WO (1) WO2021011673A2 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3658172A4 (en) 2017-07-25 2021-05-05 TrueBinding, Inc. TREATING CANCER BY BLOCKING THE INTERACTION OF TIM-3 AND HIS LIGAND
CN113711036B (zh) 2019-01-30 2025-03-18 真和制药有限公司 抗gal3抗体及其用途
CN116157151A (zh) 2020-05-26 2023-05-23 真和制药有限公司 通过阻断半乳凝素-3治疗炎性疾病的方法
WO2026082154A1 (en) * 2024-10-18 2026-04-23 Lepu Biopharma Co., Ltd. Anti-beta amyloid antibodies and uses thereof

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
WO1994009817A1 (en) 1992-11-04 1994-05-11 City Of Hope Novel antibody construct
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
WO1996033761A1 (en) 1995-04-28 1996-10-31 Medtronic, Inc. Intraparenchymal infusion catheter system
WO1997014719A1 (en) 1995-10-16 1997-04-24 Unilever N.V. A bifunctional or bivalent antibody fragment analogue
GB9524973D0 (en) 1995-12-06 1996-02-07 Lynxvale Ltd Viral vectors
US5735814A (en) 1996-04-30 1998-04-07 Medtronic, Inc. Techniques of treating neurodegenerative disorders by brain infusion
US20030068316A1 (en) * 1997-02-05 2003-04-10 Klein William L. Anti-ADDL antibodies and uses thereof
DK0979281T3 (da) 1997-05-02 2005-11-21 Genentech Inc Fremgangsmåde til fremstilling af multispecifikke antistoffer med heteromultimere og fælles bestanddele
WO2002002781A1 (en) 2000-06-30 2002-01-10 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Heterodimeric fusion proteins
EP1545582A4 (en) * 2002-10-01 2008-09-17 Univ Northwestern DIFFUSIBLE DERIVATIVES DERIVED FROM AMYLOID BETA (ADDL), ADDL SUBSTITUTE, ADDL BINDING MOLECULES, AND USES THEREOF
US20160213794A1 (en) * 2002-10-01 2016-07-28 Northwestern University Amyloid beta-derived diffusible ligands (addls), addl-surrogates, addl-binding molecules and uses thereof
CN1871259A (zh) 2003-08-22 2006-11-29 比奥根艾迪克Ma公司 具有改变的效应物功能的经改进的抗体和制备它的方法
CN101198698B (zh) 2005-03-31 2014-03-19 中外制药株式会社 通过调节多肽缔合制备多肽的方法
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
PE20090329A1 (es) * 2007-05-30 2009-03-27 Abbott Lab Anticuerpos humanizados contra el globulomero ab(20-42) y sus usos
DK2170389T3 (en) * 2007-06-12 2015-01-19 Ac Immune Sa Humanized antibodies against amyloid beta
EP2050764A1 (en) 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
US9272030B2 (en) * 2007-10-17 2016-03-01 Janssen Sciences Ireland Uc Use of tau to monitor immunotherapy
EP3663318A1 (en) 2008-01-07 2020-06-10 Amgen Inc. Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
WO2010054007A1 (en) * 2008-11-07 2010-05-14 Fabrus Llc Combinatorial antibody libraries and uses thereof
EP2593475B1 (en) * 2010-07-14 2016-03-02 Merck Sharp & Dohme Corp. Anti-addl monoclonal antibody and uses thereof
EP2906597B1 (en) * 2012-10-15 2020-04-08 Medimmune Limited Antibodies to amyloid beta

Also Published As

Publication number Publication date
EP3999532A2 (en) 2022-05-25
CN115175932B (zh) 2025-10-31
WO2021011673A3 (en) 2021-07-01
CN115175932A (zh) 2022-10-11
US20230107034A1 (en) 2023-04-06
CN121949538A (zh) 2026-05-01
CN121800915A (zh) 2026-04-07
JP2022541459A (ja) 2022-09-26
JP7685985B2 (ja) 2025-05-30
WO2021011673A2 (en) 2021-01-21
CA3147239A1 (en) 2021-01-21

Similar Documents

Publication Publication Date Title
US11891454B2 (en) Production of T cell retargeting hetero-dimeric immunoglobulins
AU2022252753B2 (en) ANTIBODIES TO a-SYNUCLEIN AND USES THEREOF
JP7399880B2 (ja) ＦｃＲｎへの増強された結合及び延長された半減期を有するＦｃ変異体
KR102952441B1 (ko) 항 비7 에이치4 항체, 그의 항원 결합 단편 및 그의 약학적 용도
JP7352973B2 (ja) 二重特異性抗体及びその使用
CN115175932B (zh) 用于治疗阿尔茨海默病的中和抗β淀粉样蛋白抗体
WO2018161872A1 (zh) 抗b7-h3抗体、其抗原结合片段及其医药用途
CN111601821B (zh) 具有对FcRn的亲和力提高以及对至少一个Fc片段受体的亲和力提高的Fc片段的变体
JP2025098167A (ja) Ｆｃｒｎアンタゴニストで抗体媒介性障害を処置する方法
JP2017529832A (ja) Ｆｃγ受容体ＩＩＢおよびＦｃε受容体に対する新規の抗体
US20190002588A1 (en) Anti-myl9 antibody
US12630615B2 (en) Neutralizing anti-amyloid beta antibodies for the treatment of Alzheimer's disease
EP4269588A1 (en) Anti-epha4 antibody
RU2795592C2 (ru) Варианты fc с повышенным связыванием с fcrn и пролонгированным периодом полувыведения
TW202615453A (zh) 單特異性及雙特異性tau結合蛋白及其組合物

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000